

4DMEDICAL RAISES \$6M IN STRONGLY SUPPORTED SPP

Highlights

- Share Purchase Plan (SPP) increased to \$6 million following approximately \$32 million of demand
- Follows on from the successful \$40 million institutional placement in March 2021
- Strong balance sheet position with cash balance exceeding \$80 million

31 March 2021: 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to confirm the successful completion of its Share Purchase Plan (“SPP”), announced on 4 March 2021.

The SPP was strongly supported by existing eligible shareholders and was substantially oversubscribed. The Company received 1,873 applications totalling approximately \$32 million at the issue price of \$1.55, the same issue price as the successful \$40 million institutional placement completed on 4 March 2021.

Given the response to the SPP and to accommodate the outstanding support of existing shareholders, 4DMedical’s Board of Directors has exercised its discretion to increase the SPP offer to \$6 million from the original \$3 million targeted.

A total of approximately 3.87 million new fully paid ordinary shares (“SPP Shares”) will be issued, representing approximately 1.33% of the Company’s ordinary shares on issue.

The Company will conduct a scale back of valid applications from eligible shareholders in accordance with the terms of the SPP as determined by the 4DMedical Board of Directors. Specifically, the scale back will take into consideration the number of shares applied for by eligible shareholders under the SPP, as well as the number of shares held by eligible shareholders at the record date of 3 March 2021.

The SPP Shares are expected to be issued on Wednesday, 7 April 2021 and commence trading on the ASX on Thursday, 8 April 2021. Holding statements are expected to be dispatched on Friday, 9 April 2021.

4DMedical Founder and CEO Andreas Fouras said:

“We are delighted with the overwhelming support from our shareholders in both the recent placement and SPP. In response to the demand for the SPP, the Board has decided to increase the size of the SPP to allow existing shareholders a larger opportunity to participate in the capital raising.

“The proceeds from the placement and SPP, together with the \$28.9 million of funding from the MRFF Frontiers initiative, provide 4DMedical with a significantly enhanced capability to execute the long-term commercialisation strategy for XVD Scanners™, which will open up an additional revenue stream for the business and drive the adoption of XV LVAS™ at medical institutions. The Company now also has balance sheet flexibility to pursue future growth opportunities.

“On behalf of the Company I would like to thank our shareholders for their support.”

Refund Process

The payment of refunds for scaled back applications, as well as late and invalid applications, is expected to commence on Friday 9 April 2021.

Refunds will be returned by cheque, or by direct credit if electronic payment instructions were held on file at the SPP Closing Date.

ENDS

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, CEO.

Contacts:

| <i>Corporate</i> | <i>Investor</i> | <i>Media</i> |
|--------------------------------|------------------------|-------------------------------|
| Charlene Stahr | Simon Hinsley | Matthew Wright |
| Company Secretary | + 61 401 809 653 | + 61 451 896 420 |
| companysecretary@4dmedical.com | shinsley@4dmedical.com | matt@nwrcommunications.com.au |

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.